165 related articles for article (PubMed ID: 6825108)
1. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum.
Bast RC; Berek JS; Obrist R; Griffiths CT; Berkowitz RS; Hacker NF; Parker L; Lagasse LD; Knapp RC
Cancer Res; 1983 Mar; 43(3):1395-401. PubMed ID: 6825108
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity.
Bast RC; Knapp RC; Mitchell AK; Thurston JG; Tucker RW; Schlossman SF
J Immunol; 1979 Nov; 123(5):1945-51. PubMed ID: 489967
[TBL] [Abstract][Full Text] [Related]
3. Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum.
Lichtenstein A; Berek J; Bast R; Spina C; Hacker N; Knapp RC; Zighelboim J
J Biol Response Mod; 1984 Aug; 3(4):371-8. PubMed ID: 6541243
[TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced ovarian malignancy with chemoimmunotherapy using autologous tumor and Corynebacterium parvum.
Gusdon JP; Homesley HD; Jobson VW; Muss HB
Obstet Gynecol; 1983 Dec; 62(6):728-35. PubMed ID: 6633998
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
Cancer Res; 1985 Sep; 45(9):4447-53. PubMed ID: 4028027
[TBL] [Abstract][Full Text] [Related]
6. Serotherapy of ovarian cancer.
Lidor Y; Bast RC
Nat Immun Cell Growth Regul; 1988; 7(4):193-215. PubMed ID: 3070370
[TBL] [Abstract][Full Text] [Related]
7. Natural killer inhibitory substance produced by the peritoneal cells of patients with ovarian cancer.
Lichtenstein AK; Berek J; Zighelboim J
J Natl Cancer Inst; 1985 Feb; 74(2):349-55. PubMed ID: 3856049
[TBL] [Abstract][Full Text] [Related]
8. Role of inflammatory neutrophils in antitumor effects induced by intraperitoneal administration of Corynebacterium parvum in mice.
Lichtenstein AK; Berek J; Kahle J; Zighelboim J
Cancer Res; 1984 Nov; 44(11):5118-23. PubMed ID: 6488171
[TBL] [Abstract][Full Text] [Related]
9. Requirements for successful immunotherapy and chemoimmunotherapy of a murine model of ovarian cancer.
Vanhaelen CP; Fisher RI
Cancer Res; 1981 Mar; 41(3):980-3. PubMed ID: 7193085
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum.
Berek JS; Knapp RC; Hacker NF; Lichtenstein A; Jung T; Spina C; Obrist R; Griffiths CT; Berkowitz RS; Parker L
Am J Obstet Gynecol; 1985 Aug; 152(8):1003-10. PubMed ID: 2992276
[TBL] [Abstract][Full Text] [Related]
11. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
[TBL] [Abstract][Full Text] [Related]
12. Successful immunotherapy with intraperitoneal Corynebacterium parvum in a murine ovarian cancer model is associated with the recruitment of tumor-lytic neutrophils into the peritoneal cavity.
Lichtenstein AK; Kahle J; Berek J; Zighelboim J
J Immunol; 1984 Jul; 133(1):519-26. PubMed ID: 6373934
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancer.
Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
Cancer Treat Rev; 1985 Dec; 12 Suppl B():23-32. PubMed ID: 3833327
[TBL] [Abstract][Full Text] [Related]
14. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
15. Intra-tumour C. parvum therapy in gastric carcinoma; a pilot study.
Dykes PW; Trejdosiewicz LK
Dev Biol Stand; 1977 Apr 13-15; 38():547-52. PubMed ID: 608548
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
[TBL] [Abstract][Full Text] [Related]
17. Intravenous Corynebacterium parvum: an adjunct to chemotherapy for resistant advanced ovarian cancer.
Rao B; Wanebo HJ; Ochoa M; Lewis JL; Oettgen HF
Cancer; 1977 Feb; 39(2):514-26. PubMed ID: 837334
[TBL] [Abstract][Full Text] [Related]
18. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial with Corynebacterium parvum.
Medenica R; Girard JP; Maurice P
Dev Biol Stand; 1977 Apr 13-15; 38():483-5. PubMed ID: 344103
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of Corynebacterium parvum and retinyl palmitate used in combination on the Lewis lung carcinoma.
Pavelic ZP; Dave S; Bialkowski S; Priore RL; Greco WR
Cancer Res; 1980 Dec; 40(12):4617-21. PubMed ID: 7438095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
